Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: J Am Med Dir Assoc. 2016 Jun 24;17(9):852–859. doi: 10.1016/j.jamda.2016.05.011

Table 7.

Other Treatments

  • Strontium ranelate can be considered as a second-line treatment option (level I).

  • Strontium ranelate should not be coprescribed with other osteoporosis treatments except calcium and vitamin D (level V).

  • Strontium ranelate should not be used in those with established cardiovascular disease or thromboembolic disease risk or those who are immobile (level III).

  • Teriparatide should be considered as a treatment for those with severe osteoporosis (T score ≤ −3.0 SD, with a recurrent fracture despite ≥ 12 months of antiresorptive therapy), and (level II).